Authors: Takimoto, CH Morrison, G Harold, N Quinn, M Monahan, BP Band, RA Cottrell, J Guemei, A Llorens, V Hehman, H Ismail, AS Flemming, D Gosky, DM Hirota, H Berger, SJ Berger, NA Chen, AP Shapiro, JD Arbuck, SG Wright, J Hamilton, JM Allegra, CJ Grem, JL

Citation: Ch. Takimoto et al., Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients, J CL ONCOL, 18(3), 2000, pp. 659-667

Authors: Shapiro, JD Harold, N Takimoto, C Hamilton, JM Vaughn, D Chen, A Steinberg, SM Liewehr, D Allegra, C Monahan, B Lash, A Grollman, F Flemming, D Behan, K Johnston, PG Haller, D Quinn, M Morrison, G Grem, JL

Citation: Jd. Shapiro et al., A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma, CLIN CANC R, 5(9), 1999, pp. 2399-2408

Authors: Toner, GC Shapiro, JD Laidlaw, CR Rischin, D Millward, MJ Wolf, M Januszewicz, H Mitchell, SV Curran, AC Matthews, JP Bishop, JF

Citation: Gc. Toner et al., Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: A randomized, crossover comparison, J CL ONCOL, 16(12), 1998, pp. 3874-3879

Authors: Shapiro, JD Phillips, KA Tannock, IF

Citation: Jd. Shapiro et al., More pharmaceutical company influence?, AUST NZ J M, 28(5), 1998, pp. 675-675